GNAQ Mutation-positive Metastatic Melanoma
1 clinical trials · Condition
◉ Watch GNAQ Mutation-positive Metastatic Melanoma
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma (NCT01328106) | GlaxoSmithKline | 2010-11-01 |
Track GNAQ Mutation-positive Metastatic Melanoma automatically
Every clearance here is in the API, with alerts when new ones post.